A new Covid-19 antibody test machine has been created by researchers at the Indian Institute of Science (IISc) in Bengaluru.
For Covid-19, the IISc established a semi-quantitative electrochemical ELISA test. Covid-induced IgM and IgG antibody levels can be determined using this test.
IISc said in a statement, “PathShodh Healthcare, a start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc), has made a significant breakthrough in developing a first-of-its-kind, semi-quantitative electrochemical ELISA test for COVID-19 IgM and IgG antibodies,”.
After due diligence validation at the Translational Health Science and Technology Institute (THSTI), Faridabad – as required by the Indian Council of Medical Research (ICMR) – the Central Drugs Standard Control Organisation (CDSCO) has granted a licence to produce the test for sale, and the scientists behind the project claim they intend to deploy the product in the market in the coming months.
The statement said, “The novelty of the technology is based on the measurement of electrochemical redox activity of IgM and IgG antibodies specific to the SARS-CoV-2 Spike Glycoprotein (S1). The S1 protein has a Receptor Binding Domain (RBD) which latches on to the ACE2 receptors on the host cells before infection. Hence, antibody tests targeting the S1 spike protein are more representative of immune response against infection compared to those that target the Nucleocapsid (N) protein,”.
PathShodh’s Lab-on-Palm platform “anuPathTM,” which interfaces with disposable test strips functionalized with an immunoreceptor unique to Covid-19 antibodies, was used to establish this test.